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INTRODUCTION
Ginseng (人参 Rén Shēn) possesses several beneficial effects 
in the prevention of diabetes, cancer, and cardiovascular disease,[1‑3] 
and therefore, it is extensively used in different therapeutic and 
health‑promoting preparations. These biological activities in ginseng 
may be attributed to the presence of bioactive compounds such 
as ginsenosides, polysaccharides, and flavonoids.[4] Among these 
bioactive compounds, ginsenosides have been extensively investi‑
gated as different ginsenosides possess varying pharmacological 
and biological activities. For instance, Rg1 and compound K (CK) 
were shown to stimulate glucose uptake in 3T3‑L1 adipocytes,[5] 
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Ginseng (人参 Rén Shēn) has been widely employed in functional foods and traditional medicines in many Asian countries. Owing to 
the high consumer demand of ginseng products, a large amount of ginseng residue is generated after extraction of ginseng. However, 
the ginseng residue still contains many bioactive compounds such as ginsenosides. The objective of this research was to convert 
ginsenosides in American ginseng (西洋參 Xī Yáng Shēn) extraction residue (AmR) by fermentation with lingzhi (靈芝 Líng Zhī, 
Ganoderma lucidum) and the fermentation products will be used for further hypoglycemic activity research. Thus, this study was 
primarily focused on the ginsenosides that have been reported to possess hypoglycemic activity. In this study, the changes in seven 
ginsenoside [Rg1, Re, Rb1, Rc, Rg3(S), compound K (CK), and Rh2(S)] in the products as affected by fermentation were investigated. 
Our results showed that the levels of ginsenosides, namely, Rg1, Rg3(S), and CK increased, while the other ginsenosides (Re, Rb1, 
and Rc) decreased during the fermentation process.
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with the former one increasing the performance of learning/memory 
in a mice model as well.[6] Furthermore, the composition of ginsen‑
osides is the major indicator of ginseng quality and species type as 
the amount and type of ginsenosides in ginseng vary depending on 
the species, age, harvest season, growth condition, and processing 
methods.[4,7,8] The ratio of ginsenoside Rb1/Rg1 in American ginseng 
(西洋參 Xī Yáng Shēn) was reported to be higher than in Asian 
ginseng (東洋參 Dōng Yáng Shēn). Despite its potential health 
benefits, ginsenosides suffer from poor bioavailability. Previous 
studies have pointed out that the conversion of ginsenoside Rb1 
into its deglycosylated metabolite CK could substantially increase 
both bioavailability and bioactivity,[9,10] with their bioavailability 
being 0.3%‑1.2% and 35.0%, respectively.[11‑14] Thus, it is important 
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to convert the major ginsenoside Rb1 into its minor metabolites for 
improved bioactivity and bioavailability.
Lingzhi (靈芝 Líng Zhī, Ganoderma lucidum) is a popular 
traditional Chinese medicine (TCM) belonging to white rot 
basidiomycete. Generally, G. lucidum is investigated for its 
pharmacological activities including hyperglycemia, hyper‑
tension, immunomodulatory, liver protection, and anti‑tumor 
effects.[15‑18] In addition, lignin‑modifying enzymes synthesized 
by G. lucidum could degrade lignins, cellulose, and hemi‑cel‑
lulose.[19] In this study, G. lucidum was employed to degrade 
lignin and cellulose in the cell walls of American ginseng 
residue (AmR) for bioconversion of ginsenosides. Several 
bioconversion methods in ginsenosides include heating, acid 
or alkaline hydrolysis, enzymatic and microbial conversion. 
Specifically, chemical conversion methods are not environment 
friendly and may cause poor selectivity and low efficiency, 
eventually reducing the biological activity of ginsenosides,[20‑22] 
whereas enzymatic conversion method is highly selective and 
environmentally compatible, especially under mild reaction 
conditions. However, the enzymes currently employed are 
not stable enough for their usage in industries.[22] On the other 
hand, microbial conversion method is more advantageous as 
it is ecofriendly, economically viable, and can be scaled up 
for good reproducibility. Consequently, microbial conversion 
is the most desirable bioconversion method for industrial ap‑
plication.[23]
In many Asian countries, abundant amounts of ginseng 
residue are produced as waste byproduct every year owing to 
its large application in manufacturing functional food products. 
Ultimately, the efficient utilization of ginseng extraction residue 
for potential application in various fields is a subject of significant 
interest. Moreover, G. lucidum is also a valuable TCM and has 
been rarely investigated for bioconversion of ginsenosides. In 
this study, we intend to study the bioconversion of ginsenosides 
in AmR by G. lucidum and determine the changes in ginsen‑
oside composition as affected by fermentation conditions of 
G. lucidum grown on AmR. This study can not only develop a 
valuable functional food ingredient by combining the benefits 
of both ginseng and lingzhi, but can also resolve the problem of 
ginseng waste management.
MATERIALS AND METHODS
Materials
American ginseng extraction residue was supplied by a local 
food company, while AmR fermentation products were prepared by 
Dr. Ting‑Jang Lu of our institute using G. lucidum (BCRC37066) 
from Bioresource Collection and Research Center, Food Industry 
Research and Development Institute (Hsinchu City, Taiwan). 
Ginsenoside standards including Re, Rg1, Rb1, Rc, Rg3(S), and 
Rh2(S) were purchased from Advantage Chemical Co. Ltd. (Taic‑
hung, Taiwan). Ginsenoside standard CK was obtained from Tauto 
Biotech Ltd. (Shanghai, China), digoxin from Sigma (St. Louis, 
MO, USA) and organic solvents acetonitrile, ethyl alcohol, and 
methyl alcohol from Mallinckrodt Baker (NJ, USA).
Instrumentation
Shaking water bath (model 905) was from Hotech (Taipei, 
Taiwan), rotary evaporator (RE111) from Buchi (Flawil, Swit‑
zerland), centrifugal vacuum concentrator (SCV100H) from Sa‑
vant (Farmingdale, NY, USA), ultrasonic processor (S4000) from 
Misonix (Farmingdale, NY, USA), and centrifuge (model 2100) 
from KUBOTA (Tokyo, Japan).
Fermentation method
The fermentation method included two steps. The first step 
was inoculum preparation. G. lucidum was cultivated in malt ex‑
tract agar with 2% ginseng residue at 25°C for 7 days. Afterward, 
G. lucidum was harvested and then seeded in AmR at 1% w/w 
(low inoculation), 5% w/w (medium inoculation), and 10% (w/w) 
(high inoculation) of inoculum quantity for subsequent incubation 
at 25°C for 4, 8, or 13 days.
Sample preparation
A method based on Wang, et al.,[24] was modified for extrac‑
tion of ginsenosides from unfermented AmR and G. lucidum fer‑
mented AmR (FAmR). One gram sample was mixed with 20 mL 
of 80% methanol–water solution at a sample to solvent ratio of 
1:20 and shaken for 1 h at 50°C, followed by filtering through 
a Whatman No. 1 filter paper, concentrating under vacuum at 
40°C, and freeze‑drying. Next, 50 mg of the extract was dissolved 
in 1 mL of deionized water and purified by using Sep‑Pak C18 
Cartridge (Phenomenex, Inc., Torrance, CA, USA) by activating 
sequentially with 5 mL each of methanol and deionized water. The 
extract solution (1 mL) was then passed through the C18 Cartridge, 
washed with 5 mL of deionized water, and finally eluted with 5 mL 
of methanol. The eluted methanol extract was evaporated to dry‑
ness under vacuum, the residue redissolved in 1 mL of methanol, 
filtered through a 0.2 µm membrane filter (Chrom Tech, Inc., Min‑
nesota, USA), and 10 µL injected into high‑performance liquid 
chromatography (HPLC) for analysis.
HPLC analysis of ginsenosides
For the separation of various ginsenosides in unfermented 
AmR and FAmR, a method based on Kim et al.,[25] was modified 
and used. A Hitachi HPLC system (Toyko, Japan) consisted of 
a chromatographic pump (L‑7100), autosampler (L‑7200), and 
UV‑VIS detector (L‑7420). A C18 Atlantis column (4.6 mm 
ID × 150 mm, 3 µm particle size) from Waters and a binary solvent 
system of deionized water (A) and acetonitrile (B) was used for 
separation with the following gradient conditions: 79% A and 21% 
B initially, increased to 22% B at 6 min, 23% B at 7 min, 24% B 
at 25 min, 30% B at 30 min, 32% B at 40 min, 50% B at 45 min, 
65% B at 60 min, 100% B at 61 min, and maintained until 71 min. 
The flow rate was maintained at 0.8 mL/min, column temperature 
at 30°C, and detection wavelength at 203 nm.
Quantification of ginsenosides in ginseng residue and its 
fermentation products
The quantification of ginsenosides in unfermented AmR 
and FAmR samples was conducted by incorporating an internal 
standard into the ginsenoside standard solution and developing 
standard curves based on the peak area ratio versus the concen‑
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tration ratio. Digoxin was selected as the internal standard and a 
concentration of 100 µM was prepared in methanol. The concen‑
tration range of 0.25‑400 µM for each ginsenoside standard Rg1, 
Re, Rb1, Rc, Rg3(S), CK, and Rh2(S) was prepared separately 
and mixed with digoxin for a final concentration of 60 µM. The 
calibration curves were plotted by standard peak area (As)/inter‑
nal standard peak area (Ai) versus standard concentration (Cs)/
internal standard concentration (Ci) in µM and then submitted to 
linear regression analysis in Microsoft Excel software to obtain 
regression equation for each ginsenoside. The quantity of each 
ginsenoside was calculated by the regression equation.
Determination of recovery
Different amounts of each ginsenoside standard were added 
separately to ginseng waste powder and then subjected to ex‑
traction and HPLC analysis. The recovery of each ginsenoside 
standard was calculated based on the ratio of the amount initially 
added to that determined after HPLC analysis. The recovery of 
each ginsenoside was 96.5 ± 0.71% for Rg1, 89.5 ± 3.54% for 
Re, 84.5 ± 2.12% for Rb1, 92.5 ± 10.61% for Rc, 87.5 ± 6.36% 
for Rg3, 93 ± 1.41% for CK, and 81 ± 2.38% for Rh2.
Statistical analysis
Each measurement was conducted in triplicate and the results 
were evaluated by analysis of variance (ANOVA) and Duncan’s 
multiple range test for significance in mean comparison (P = 0.05) 
by using the SAS software system.
RESULTS AND DISCUSSION
The structure of ginsenosides is shown in Figure 1. In this study, 
we primarily focused on the ginsenosides that have been reported 
to possess hypoglycemic activity and the changes in these ginsen‑
osides during fermentation. Seven ginsenosides, namely, Rg1, Re, 
Rb1, Rc, Rg3(S), CK, and Rh2(S), were analyzed in ginsenoside 
standards and fermentation samples by using HPLC. Figures 2 and 3 
depict the HPLC chromatogram for separation of ginsenosides in 
ginsenoside standards mixture and unfermented AmR as well as 
FAmR samples on different days of fermentation, respectively. Our 
results showed that the content of ginsenosides Rb1, Re, and Rc in 
AmR was higher than the other ginsenosides [Table 1 and Figure 4], 
with their levels amounting to 49.66, 23.61, and 15.05 µmol/g, 
respectively. However, Ligor et al.,[26] have reported the amount 
of Rb1 to be significantly higher than the other ginsenosides in 
American ginseng, and this contrasting result may be due to varia‑
tion in the sample variety. In the absence of any fermentation, the 
total content of ginsenosides Rb1, Re, and Rc in unfermented AmR 
was 90.83 µmol/g, and after fermentation with G. lucidum for 
13 days, the amount diminished to a same level of 11.06 µmol/g 
for both 1% low and 5% medium inoculations and to 10.84 µmol/g 
for 10% high inoculation. However, compared to without fermen‑
tation (1.72 µmol/g), the total amount of other three ginsenosides 
Rg1, Rg3(S), and CK soared, attaining a level of 5.33, 6.07, and 
5.06 µmol/g for 1%, 5%, and 10% inoculations, respectively. The 
results showed that the total amount of seven ginsenosides was 
dramatically decreased during fermentation, which might be at‑
tributed to the reason that some major transformed ginsenosides 
in the fermentation products were not analyzed.
For protopanaxadiol type ginsenosides, the ginsenoside Rb1 
levels in unfermented AmR, FAmR at 1% inoculation, FAmR at 
5% inoculation, and FAmR at 10% inoculation were 49.66, 8.99, 
10.08, and 8.40 µmol/g, respectively, while much lower values of 
15.05, 1.42, 0.86, and 1.70 µmol/g were obtained for ginsenoside 
Rc, indicating a decreasing trend in the content of Rb1 and Rc dur‑
ing fermentation. On the contrary, both Rg3(S) and CK increased 
upon fermentation with their levels equaling 1.57 and 0.15 µmol/g 
for unfermented AmR, 4.00 and 0.05 µmol/g for FAmR at 1% in‑
oculation, 3.21 and 0.36 µmol/g for FAmR at 5% inoculation, and 
2.76 and 0.37 µmol/g for FAmR at 10% inoculation, respectively. 
This observed trend in ginsenoside levels during fermentation 
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Figure 2. HPLC chromatogram for separation of seven ginsenoside 
standards mixed with an internal standard digoxin (IS): 1, Rg1; 2, 
Re; 3, Rb1; 4, Rc; 5, Rg3(s); 6, CK; 7, Rh2(s). The concentration of each 
ginsenoside standard was 50 μM, while that of IS digoxin was 60 μM. 
HPLC conditions are described in the section Materials and Methods
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Compound R1 R2 R3
Protopanaxadiol
Rb1 ‑O‑Glc2‑Glc ‑O‑Glc6‑Glc ‑H
Rc ‑O‑Glc2‑Glc ‑O‑Glc6‑Araf ‑H
Rg3 ‑O‑Glc2‑Glc ‑O‑H ‑H
Rh2 ‑O‑Glc ‑O‑H ‑H
Compound K ‑O‑H ‑O‑Glc ‑H
Protopanaxatriol
Re ‑O‑H ‑O‑Glc2‑Rha ‑O‑Glc
Rg1 ‑O‑H ‑O‑Glc ‑O‑Glc
Araf: α‑l‑arabinose (furanose); Glc: β‑d‑glucose; Rha: α‑l‑rhamnose
Figure 1. The chemical structures of ginsenosides
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may be caused by the conversion of ginsenoside Rb1 into Rg3 by 
removal of two glucose moieties from position C‑20 and Rb1 into 
CK by elimination of two glucose units from C‑3 followed by one 
glucose from C‑20 position. Such conversions were reported by 
Takino[27] as well as Qian and Cai,[28] with the former demonstrating 
the transformation of Rb1 into its deglycosylated product Rg3 after 
incubation with 0.1 M HCl at 37°C, while the same conversion was 
shown in gastrointestinal tract by the latter after oral administra‑
tion of Rb1 to rats. Additionally, deglycosylation and oxygenation 
were identified as the two major metabolic pathways responsible 
for conversion of Rb1 into its metabolites. A bioconversion of Rb1 
into CK by a β‑glucosidase active bacterium Leuconostoc citreum 
LH1 was also reported by Quan, et al.[29] Likewise, conversion of 
Rc into Rg3 and CK can also occur by removal of one glucose and 
one arabinose from C‑20 position for the former and elimination 
of two glucose units from C‑3 followed by one arabinose from 
C‑20 for the latter. A fungus‑mediated bioconversion of Rc into 
CK by Fusarium sacchari was reported by Han, et al.[30] Thus, 
the increase in ginsenoside Rg3 and CK levels may be caused by 
bioconversion of Rb1 and Rc during fermentation of AmR with 
G. lucidum.
Upon fermentation for 13 days, the level of protopanaxatriol 
type ginsenoside Re significantly dropped, with its content in 
unfermented AmR, FAmR at 1% inoculation, FAmR at 5% in‑
oculation, and FAmR at 10% inoculation amounting to 23.61, 
0.40, 0.00, and 0.20 µmol/g, respectively. The ginsenoside Rg1 
was undetected in unfermented AmR; however, its amount rose 
to 1.27, 2.49, and 1.93 µmol/g during fermentation with 1%, 5%, 
and 10% inoculations, respectively. Theoretically, ginsenoside Re 
can be converted into Rg1 by removal of one rhamnose from C‑6 
Figure 3. HPLC chromatogram for separation of ginsenosides in unfermented American ginseng residue (AmR) and G. lucidum fermented 
AmR (FAmR). (a) AmR without fermentation; (b) FAmR‑4, AmR fermented with G. lucidum at 10% inoculation for 4 days; (c) FAmR‑8, AmR fermented 
with G. lucidum at 10% inoculation for 8 days; (d) FAmR‑13, AmR fermented with G. lucidum at 10% inoculation for 13 days. 1, Rg1; 2, Re; 3, Rb1; 4, 
Rc; 5, Rg3(s); 6, CK. Sample concentration, 2000 μg/mL; IS concentration, 60 μM
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position. Therefore, we suggest that the increase in Rg1 level in 
FAmR samples may be caused by conversion of Re during fer‑
mentation of AmR. Besides ginsenosides, the lingzhi triterpenes, 
including ganoderic acid A, B, C2, D, E, F, G, and F, were also 
analyzed. However, all of these ganoderic acids were not detected 
in the fermentation samples. This might be attributed to the in‑
sufficient fermentation time for ganoderic acid production (data 
not shown). Additionally, the lingzhi bioactive polysaccharide 
maker (1,3)‑β‑d‑glucan, which is a large molecule, also increased 
during fermentation (unpublished data). Thus, the fermentation 
products combined the benefits of both ginseng and G. lucidum.
The major ginsenosides Rg1 and Rg3(S) found in FAmR 
samples had been shown to possess several biological activities. 
In several studies, Rg1 has been demonstrated to possess hypogly‑
cemic activity and increase the performance of learning/memory 
as well in mice model.[5,6,31] Nevertheless, vasodilating, hepatopro‑
tective, and neuroprotective effects were reported for ginsenoside Ta
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Figure 4. Changes in ginsenoside content during fermentation of American 
ginseng residues with G. lucidum at (a) 1% low inoculation, (b) 5% 
medium inoculation, and (c) 10% high inoculation
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Rg3.[32‑34] Interestingly, a higher pharmacological activity was 
shown by minor ginsenosides like Rg3 and CK when compared 
to the major ones (Rb1, Rc, and Re).[20,35] However, the amount of 
Rg3 is extremely low in normal ginseng, and hence, it is important 
to develop methods to convert major ginsenosides like Rb1 into mi‑
nor Rg3 for good biological activity.[36] Among several conversion 
methods, enzymatic and microbial conversions are often preferred 
for production of minor ginsenosides. Using an enzymatic conver‑
sion method, Quan, et al.,[37] converted the ginsenoside Rb1 into 
Rg3 by employing a recombinant β‑glucosidase (Bgp1) from Mi-
crobacterium esteraromaticum. In two different studies involving 
microbial conversion method, Microbacterium sp. (GS514 strain) 
and Acremonium strictum were used for bioconversion of Rg3.[36,38] 
Likewise, Chi and Ji[39] have utilized the fungus Aspergillus niger 
for microbial bioconversion of Re into Rg1. Actually, in micro‑
bial conversion methods, microorganisms are cultivated in liquid 
medium by reacting directly with the substrate (ginsenoside Rb1). 
However, the ginsenoside substrate is expensive and these microbial 
methods require further purification of ginsenoside products. Thus, 
microbial conversion methods may not be economically viable and 
practically feasible especially for application in industries. In this 
study, AmR was used as the fermentation medium for G. lucidum 
which degrades the cell wall of AmR first and, thus, may not react 
directly with the substrate (ginsenoside Rb1). Despite the long 
time duration required by this method, the fermentation products 
obtained could be utilized directly without further purification, 
thereby making our bioconversion method both economically 
and practically feasible for developing valuable new functional 
food ingredient by combining the benefits of both ginseng and 
G. lucidum. It is worth pointing out that G. lucidum is rarely used 
for the bioconversion of ginsenosides and utilization of ginseng 
residue for functional food development would be a “wealth from 
waste,” besides solving the problem of waste disposal. This is only 
a preliminary study to investigate the bioconversion of ginsenosides 
in the AmR by lingzhi (G. lucidum) and further research is necessary 
to elucidate the detailed bioconversion procedure.
CONCLUSION
An eco‑friendly and economically viable microbial fermentation 
method was developed for bioconversion of ginsenosides in American 
ginseng extraction residue into more bioactive fermentation products. 
Upon fermentation with G. lucidum, the amount of ginsenosides Re, 
Rb1, and Rc declined, while Rg1 and Rg3(S) increased. Thus, this 
study could not only develop a valuable new functional food ingredi‑
ent by combining the benefit of both ginseng and lingzhi, but also 
resolved the problem of ginseng waste management.
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